Harbin Medical University
Clinical trials sponsored by Harbin Medical University, explained in plain language.
-
New combo therapy aims to wipe out aggressive breast cancer before surgery
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a PARP inhibitor (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early high-risk triple negative breast cancer that has a specific genetic marker (HRD positiv…
Phase: NA • Sponsor: Harbin Medical University • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
New hope for tough-to-treat colorectal cancer: combo therapy enters human testing
Disease control Not yet recruitingThis early-phase study tests a combination of two drugs—aipalirovorelizumab (QL1706) and fruquintinib—in 18 adults with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors or slow disease prog…
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New drug cocktail aims to shrink Hard-to-Treat breast tumors
Disease control Not yet recruitingThis early-phase study tests whether adding pirfenidone to standard immunotherapy (camrelizumab) and chemotherapy can shrink tumors in 12 people with advanced triple-negative breast cancer. Participants must have already tried first-line treatment. The goal is to see how many pat…
Phase: PHASE1, PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated May 18, 2026 12:07 UTC